再鼎医药(纳斯达克代码:ZLAB)27日盘前大涨5.5%,引发市场广泛关注。
从公司最新财报来看,再鼎医药2024财年总收入达到3.99亿美元,同比增长50%,业绩持续向好是推动其股价上涨的重要原因。其核心产品卫伟迦和卫力迦2024年销售收入更是达到9360万美元,产品收入呈现强劲增长势头。
此外,公司研发管线取得重大进展,也推升了投资者对其长期成长前景的信心。具有潜力成为同类首创且同类最佳药物的ZL-1310 (DLL3 ADC)用于治疗小细胞肺癌临床试验取得令人振奋的结果,ORR高达74%。同时公司的另一创新药物KarXT用于治疗精神分裂症的新药申请也已获NMPA受理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.